Skip to main content
Top
Published in: Current Infectious Disease Reports 4/2012

01-08-2012 | Central Nervous System and Eye Infections (KC Bloch, Section Editor)

Rhino-Orbital-Cerebral Mucormycosis

Authors: Maria N. Gamaletsou, Nikolaos V. Sipsas, Emmanuel Roilides, Thomas J. Walsh

Published in: Current Infectious Disease Reports | Issue 4/2012

Login to get access

Abstract

This review focuses on sinus, sino-orbital, and rhinocerebral infection caused by the Mucorales. As the traditional term of “rhinocerebral” mucormycosis omits the critical involvement of the eye, the more comprehensive term as rhino-orbital-cerebral mucormycosis (ROCM) is used. The most common underlying illnesses of ROCM are diabetes mellitus, hematological malignancies, hematopoietic stem cell transplantation, and solid organ transplantation. Sporangiospores are deposited in the nasal turbinates and paranasal sinuses in immunocompromised patients. Qualitative and quantitative abnormalities of neutrophils, monocytes and macrophages increase the risk for development of mucormycosis. Altered iron metabolism also is a critical factor in the pathogenesis of patients with diabetes mellitus who are at risk for ROCM. Angioinvasion with thrombosis and tissue necrosis is a key pathophysiological feature of human Mucorales infection. The ethmoid sinus is a critical site from which sinus mucormycosis may extend through the lamina papyracea into the orbit, extraocular muscles, and optic nerve. The brain may be seeded by invasion of the ethmoidal and orbital veins, which drain into the cavernous sinuses. Diplopia and ophthalmoplegia may be the earliest manifestations of cavernous sinus syndrome before changes are apparent on diagnostic imaging modalities. Negative diagnostic imaging does not exclude cavernous sinus mucormycosis. Mucormycosis of the maxillary sinus has a constellation of clinical features that are different from that of ethmoid sinus mucormycosis. A painful black necrotic ulceration may develop on the hard palate, indicating extension from the maxillary sinus into the oral cavity. Orbital apex syndrome is an ominous complication of mucormycosis of the orbit. Once within the orbital compartment, organisms may extend posteriorly to the optic foramen, where the ophthalmic artery, ophthalmic nerve and optic nerve are threatened by invasion, edema, inflammation and necrosis. Early diagnosis of sinus mucormycosis is critical for prevention of extension to orbital and cerebral tissues. Optimal therapy requires a multidisciplinary approach that relies on prompt institution of appropriate antifungal therapy with amphotericin B, reversal of underlying predisposing conditions, and, where possible, surgical debridement of devitalized tissue. Outcomes are highly dependent upon the degree of immunosuppression, site and extent of infection, timeliness of therapy, and type of treatment provided. New modalities for early diagnosis and therapeutic intervention are critically needed for improved outcome of patients with ROCM.
Literature
1.
go back to reference Walsh TJ, Bloom BE, Kontoyiannis DP. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis. 2012;54:S1–4.PubMed Walsh TJ, Bloom BE, Kontoyiannis DP. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis. 2012;54:S1–4.PubMed
2.
go back to reference Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Mucormycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517–25.PubMed Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Mucormycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004;17:517–25.PubMed
3.
go back to reference • Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64. Important data describing temporal patterns of increasing mucormycosis in transplant patients.PubMed • Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64. Important data describing temporal patterns of increasing mucormycosis in transplant patients.PubMed
4.
go back to reference Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of mucormycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMed Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of mucormycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMed
5.
go back to reference • Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54:S8–S15. Valuable review of current understanding of nomenclature and molecular taxonomy of mucorales.PubMed • Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis. 2012;54:S8–S15. Valuable review of current understanding of nomenclature and molecular taxonomy of mucorales.PubMed
6.
go back to reference Lanternier F, Dannaoui E, Morizot G, French Mycosis Study Group, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54:S35–43.PubMed Lanternier F, Dannaoui E, Morizot G, French Mycosis Study Group, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54:S35–43.PubMed
7.
go back to reference • Larone D. Identification of medically important fungi. ASM Press; 2012. New edition of important diagnostic text. • Larone D. Identification of medically important fungi. ASM Press; 2012. New edition of important diagnostic text.
8.
go back to reference Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24:411–45.PubMed Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24:411–45.PubMed
9.
go back to reference Petraitis V, Petraitiene R, Antachopoulos C, et al. Increased virulence of Cunninghamella bertholetiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Medical Mycol (in press). Petraitis V, Petraitiene R, Antachopoulos C, et al. Increased virulence of Cunninghamella bertholetiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism. Medical Mycol (in press).
10.
go back to reference O'Connell MA, Pluss JL, Schkade P, et al. Rhizopus-induced hypersensitivity pneumonitis in a tractor driver. J Allergy Clin Immunol. 1995;95:779–80.PubMed O'Connell MA, Pluss JL, Schkade P, et al. Rhizopus-induced hypersensitivity pneumonitis in a tractor driver. J Allergy Clin Immunol. 1995;95:779–80.PubMed
11.
go back to reference Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.PubMed Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.PubMed
12.
go back to reference Levitz SM, Selsted ME, Ganz T, et al. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986;154:483–9.PubMed Levitz SM, Selsted ME, Ganz T, et al. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis. 1986;154:483–9.PubMed
13.
go back to reference • Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against Zygomycetes. Clin Infect Dis. 2012;54 Suppl 1:S61–6. Comprehensive review of innate host defenses against mucorales. • Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against Zygomycetes. Clin Infect Dis. 2012;54 Suppl 1:S61–6. Comprehensive review of innate host defenses against mucorales.
14.
go back to reference Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982;38:487–95.PubMed Diamond RD, Clark RA. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982;38:487–95.PubMed
15.
go back to reference Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis. 1984;150:752–60.PubMed Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis. 1984;150:752–60.PubMed
16.
go back to reference Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucomycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150–60.PubMed Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucomycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest. 1984;74:150–60.PubMed
17.
go back to reference Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621–7.PubMed Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621–7.PubMed
18.
go back to reference Bagdade JD. Phagocytic and microbicidal function in diabetes mellitus. Acta Endocrinol Suppl (Copenh). 1976;205:27–34. Bagdade JD. Phagocytic and microbicidal function in diabetes mellitus. Acta Endocrinol Suppl (Copenh). 1976;205:27–34.
19.
go back to reference Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1–13.PubMed Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1–13.PubMed
20.
go back to reference Baldwin DA, De Sousa DM, Von Wandruszka RM. The effect of pH on the kinetics of iron release from human transferrin. Biochim Biophys Acta. 1982;719:140–6.PubMed Baldwin DA, De Sousa DM, Von Wandruszka RM. The effect of pH on the kinetics of iron release from human transferrin. Biochim Biophys Acta. 1982;719:140–6.PubMed
21.
go back to reference Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31:1109–14.PubMed Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes. 1982;31:1109–14.PubMed
22.
go back to reference Espinoza CG, Halkias DG. Pulmonary mucormycosis as a complication of chronic salicylate poisoning. Am J Clin Pathol. 1983;80:508–11.PubMed Espinoza CG, Halkias DG. Pulmonary mucormycosis as a complication of chronic salicylate poisoning. Am J Clin Pathol. 1983;80:508–11.PubMed
23.
go back to reference Lewis LL, Hawkins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonicaciduria. Pediatr Infect Dis J. 1990;9:851–4.PubMed Lewis LL, Hawkins HK, Edwards MS. Disseminated mucormycosis in an infant with methylmalonicaciduria. Pediatr Infect Dis J. 1990;9:851–4.PubMed
24.
go back to reference Ibrahim A, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54:S16–22.PubMed Ibrahim A, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54:S16–22.PubMed
25.
go back to reference de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843–50.PubMed de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47:1843–50.PubMed
26.
go back to reference Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18:660–7.PubMed Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18:660–7.PubMed
27.
go back to reference Boelaert JR, van Roost GF, Vergauwe PL, et al. The role of desferrioxamine in dialysis-associated mucomycosis: report of three cases and review of the literature. Clin Nephrol. 1988;29:261–6.PubMed Boelaert JR, van Roost GF, Vergauwe PL, et al. The role of desferrioxamine in dialysis-associated mucomycosis: report of three cases and review of the literature. Clin Nephrol. 1988;29:261–6.PubMed
28.
go back to reference Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307–12.PubMed Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24:307–12.PubMed
29.
go back to reference Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–86.PubMed Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–86.PubMed
30.
go back to reference Ibrahim AS, Spellberg B, Avanessian V, et al. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778–83.PubMed Ibrahim AS, Spellberg B, Avanessian V, et al. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005;73:778–83.PubMed
31.
go back to reference Chamilos G, Russell LE, Jianhua H, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A. 2008;105:9367–72.PubMed Chamilos G, Russell LE, Jianhua H, et al. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A. 2008;105:9367–72.PubMed
32.
go back to reference van de Veerdonk FL, Kullberg BJ, van der Meer JW, et al. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol. 2008;11:305–12.PubMed van de Veerdonk FL, Kullberg BJ, van der Meer JW, et al. Host-microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol. 2008;11:305–12.PubMed
33.
go back to reference Chamilos G, Lewis RE, Lamaris G, et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008;52:722–4.PubMed Chamilos G, Lewis RE, Lamaris G, et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008;52:722–4.PubMed
34.
go back to reference Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect. 2006;12:404–9.PubMed Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin Microbiol Infect. 2006;12:404–9.PubMed
35.
go back to reference Warris A, Netea MG, Verweij PE, et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol. 2005;43:613–21.PubMed Warris A, Netea MG, Verweij PE, et al. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi. Med Mycol. 2005;43:613–21.PubMed
36.
go back to reference Cortez KJ, Lyman CA, Lempicki R, et al. Comparative functional genomics of innate host defense molecules in human monocytes infected with Aspergillus fumigatus and Rhizopus Oryzae (abstr M-1773/393). In 46th Interscience Conference Antimicrob. Agents Chemother. San Francisco CA; 2006. Cortez KJ, Lyman CA, Lempicki R, et al. Comparative functional genomics of innate host defense molecules in human monocytes infected with Aspergillus fumigatus and Rhizopus Oryzae (abstr M-1773/393). In 46th Interscience Conference Antimicrob. Agents Chemother. San Francisco CA; 2006.
37.
go back to reference Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191:1180–7.PubMed Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191:1180–7.PubMed
38.
go back to reference Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella bertholetiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. Med Mycol. 2010;48:720–4.PubMed Simitsopoulou M, Georgiadou E, Walsh TJ, Roilides E. Cunninghamella bertholetiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp. Med Mycol. 2010;48:720–4.PubMed
39.
go back to reference Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992–1993: Results of population- based laboratory active surveillance. Clin Infect Dis. 1998;27:1138–47.PubMed Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992–1993: Results of population- based laboratory active surveillance. Clin Infect Dis. 1998;27:1138–47.PubMed
40.
go back to reference Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007;44:1089–90.PubMed Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007;44:1089–90.PubMed
41.
go back to reference Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Mucormycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851–6.PubMed Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Mucormycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851–6.PubMed
42.
go back to reference Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMed Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMed
43.
go back to reference • Lewis RE, Liao G, Wang W, et al. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348–55. Valuable study of mechanisms of voriconazole in selecting for Rhizopus oryzae.PubMed • Lewis RE, Liao G, Wang W, et al. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348–55. Valuable study of mechanisms of voriconazole in selecting for Rhizopus oryzae.PubMed
44.
go back to reference Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.PubMed Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39:743–6.PubMed
45.
go back to reference Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Mucormycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.PubMed Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Mucormycosis in a Tertiary-Care Cancer Center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.PubMed
46.
go back to reference Marty FM, Cosimi LA, Baden LR. Breakthrough mucormycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950–2.PubMed Marty FM, Cosimi LA, Baden LR. Breakthrough mucormycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350:950–2.PubMed
47.
go back to reference Oren H. Breakthrough mucormycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770–1.PubMed Oren H. Breakthrough mucormycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis. 2005;40:770–1.PubMed
48.
go back to reference Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive mucormycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584–7.PubMed Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive mucormycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584–7.PubMed
49.
go back to reference Vigouroux S, Morin O, Moreau P, et al. Mucormycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: Attention required. Clin Infect Dis. 2005;40:E35–7.PubMed Vigouroux S, Morin O, Moreau P, et al. Mucormycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: Attention required. Clin Infect Dis. 2005;40:E35–7.PubMed
50.
go back to reference Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal disease after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.PubMed Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal disease after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.PubMed
51.
go back to reference Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Mucormycosis–a case report and overview of the disease in India. Mycoses. 2007;50:247–54.PubMed Diwakar A, Dewan RK, Chowdhary A, Randhawa HS, Khanna G, Gaur SN. Mucormycosis–a case report and overview of the disease in India. Mycoses. 2007;50:247–54.PubMed
52.
go back to reference Anaissie EJ, Shikhani AH. Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope. 1985;95:1107–13.PubMed Anaissie EJ, Shikhani AH. Rhinocerebral mucormycosis with internal carotid occlusion: report of two cases and review of the literature. Laryngoscope. 1985;95:1107–13.PubMed
53.
go back to reference Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–62.PubMed Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–62.PubMed
54.
go back to reference Varghese A, Thomas S. Orbital apex syndrome secondary to mucormycosis after a tooth extraction in an immunocompetent patient. Ear Nose Throat J. 2010;89:E24–6.PubMed Varghese A, Thomas S. Orbital apex syndrome secondary to mucormycosis after a tooth extraction in an immunocompetent patient. Ear Nose Throat J. 2010;89:E24–6.PubMed
55.
go back to reference Feeley MA, Righi PD, Davis TE, Greist A. Mucormycosis of the paranasal sinuses and septum. Otolaryngol Head Neck Surg. 1999;120:750.PubMed Feeley MA, Righi PD, Davis TE, Greist A. Mucormycosis of the paranasal sinuses and septum. Otolaryngol Head Neck Surg. 1999;120:750.PubMed
56.
go back to reference Humphry RC, Wright G, Rich WJ, Simpson R. Acute proptosis and blindness in a patient with orbital phycomycosis. J R Soc Med. 1989;82:304–5.PubMed Humphry RC, Wright G, Rich WJ, Simpson R. Acute proptosis and blindness in a patient with orbital phycomycosis. J R Soc Med. 1989;82:304–5.PubMed
57.
go back to reference Parthiban K, Gnanaguruvelan S, Janaki C, et al. Rhinocerebral mucormycosis. Mycoses. 1998;41:51–3.PubMed Parthiban K, Gnanaguruvelan S, Janaki C, et al. Rhinocerebral mucormycosis. Mycoses. 1998;41:51–3.PubMed
58.
go back to reference Anand VK, Alemar G, Griswold Jr JA. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope. 1992;102:656–62.PubMed Anand VK, Alemar G, Griswold Jr JA. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope. 1992;102:656–62.PubMed
59.
go back to reference Gokcil Z, Odabasi Z, Kutukcu Y, et al. Rhino-orbito-cerebral mucormycosis. J Neurol. 1998;245:689–90.PubMed Gokcil Z, Odabasi Z, Kutukcu Y, et al. Rhino-orbito-cerebral mucormycosis. J Neurol. 1998;245:689–90.PubMed
60.
go back to reference Smith JL, Stevens DA. Survival in cerebro-rhino-orbital mucormycosis and cavernous sinus thrombosis with combined therapy. South Med J. 1986;79:501–4.PubMed Smith JL, Stevens DA. Survival in cerebro-rhino-orbital mucormycosis and cavernous sinus thrombosis with combined therapy. South Med J. 1986;79:501–4.PubMed
61.
go back to reference Galetta SL, Wulc AE, Goldberg HI, et al. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol. 1990;28:103–7.PubMed Galetta SL, Wulc AE, Goldberg HI, et al. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol. 1990;28:103–7.PubMed
62.
go back to reference Chawla B, Sharma S, Kashyap S, Kabra SK, Pushker N, Bajaj MS. Primary orbital mycosis in immunocompetent infants. J AAPOS. 2011;15:211–3.PubMed Chawla B, Sharma S, Kashyap S, Kabra SK, Pushker N, Bajaj MS. Primary orbital mycosis in immunocompetent infants. J AAPOS. 2011;15:211–3.PubMed
63.
go back to reference Mbarek C, Zribi S, Khamassi K, Hariga I, Ouni H, Ben Amor M, Ben Gamra O, El Khedim A. Rhinocerebral mucormycosis: five cases and a literature review. B-ENT. 2011;7:189–93.PubMed Mbarek C, Zribi S, Khamassi K, Hariga I, Ouni H, Ben Amor M, Ben Gamra O, El Khedim A. Rhinocerebral mucormycosis: five cases and a literature review. B-ENT. 2011;7:189–93.PubMed
64.
go back to reference Ketenci I, Unlü Y, Kaya H, Somdaş MA, Kontaş O, Oztürk M, Vural A. Rhinocerebral mucormycosis: experience in 14 patients. J Laryngol Otol. 2011;125:e3.PubMed Ketenci I, Unlü Y, Kaya H, Somdaş MA, Kontaş O, Oztürk M, Vural A. Rhinocerebral mucormycosis: experience in 14 patients. J Laryngol Otol. 2011;125:e3.PubMed
65.
go back to reference Lazo A, Wilner HI, Metes JJ. Craniofacial mucormycosis: computed tomographic and angiographic findings in two cases. Radiology. 1981;139:623–6.PubMed Lazo A, Wilner HI, Metes JJ. Craniofacial mucormycosis: computed tomographic and angiographic findings in two cases. Radiology. 1981;139:623–6.PubMed
66.
go back to reference Greenberg MR, Lippman SM, Grinnell VS, Colman MF, Edwards Jr JE. Computed tomographic findings in orbital Mucor. West J Med. 1985;143:102–3.PubMed Greenberg MR, Lippman SM, Grinnell VS, Colman MF, Edwards Jr JE. Computed tomographic findings in orbital Mucor. West J Med. 1985;143:102–3.PubMed
67.
go back to reference Press GA, Weindling SM, Hesselink JR, Ochi JW, Harris JP. Rhinocerebral mucormycosis: MR manifestations. J Comput Assist Tomogr. 1988;12:744–9.PubMed Press GA, Weindling SM, Hesselink JR, Ochi JW, Harris JP. Rhinocerebral mucormycosis: MR manifestations. J Comput Assist Tomogr. 1988;12:744–9.PubMed
68.
go back to reference Deshazo RD. Syndromes of invasive fungal sinusitis. Med Mycol. 2009;47:S309–14.PubMed Deshazo RD. Syndromes of invasive fungal sinusitis. Med Mycol. 2009;47:S309–14.PubMed
69.
go back to reference Yeh S, Foroozan R. Orbital apex syndrome. Curr Opin Ophthalmol. 2004;15:490–8.PubMed Yeh S, Foroozan R. Orbital apex syndrome. Curr Opin Ophthalmol. 2004;15:490–8.PubMed
70.
71.
go back to reference Karakurum B, Karatas M, Cagici AC, et al. Mucormycosis presenting with painful ophthalmoplegia. Acta Neurol Belg. 2005;105:201–5.PubMed Karakurum B, Karatas M, Cagici AC, et al. Mucormycosis presenting with painful ophthalmoplegia. Acta Neurol Belg. 2005;105:201–5.PubMed
72.
go back to reference Balch K, Phillips PH, Newman NJ. Painless orbital apex syndrome from mucormycosis. J Neuroophthalmol. 1997;17:178–82.PubMed Balch K, Phillips PH, Newman NJ. Painless orbital apex syndrome from mucormycosis. J Neuroophthalmol. 1997;17:178–82.PubMed
73.
go back to reference Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden R, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 Suppl 1:S55–60.PubMed Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden R, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 Suppl 1:S55–60.PubMed
74.
go back to reference Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have mucormycosis. Clin Infect Dis. 2008;47:503–9.PubMed Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with Hematologic malignancy who have mucormycosis. Clin Infect Dis. 2008;47:503–9.PubMed
75.
go back to reference Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;108:616–8.PubMed Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;108:616–8.PubMed
76.
go back to reference McDermott NE, Barrett J, Hipp J, et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e64–9.PubMed McDermott NE, Barrett J, Hipp J, et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e64–9.PubMed
77.
go back to reference Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary mucormycosis. J Clin Microbiol. 2008;46:3690–702.PubMed Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary mucormycosis. J Clin Microbiol. 2008;46:3690–702.PubMed
78.
go back to reference Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90:635–48.PubMed Blitzer A, Lawson W, Meyers BR, Biller HF. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1980;90:635–48.PubMed
79.
go back to reference Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39:3–22.PubMed Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol. 1994;39:3–22.PubMed
80.
go back to reference Antachopoulos C, Meletiadis J, Roilides E, et al. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol. 2006;44:553–60.PubMed Antachopoulos C, Meletiadis J, Roilides E, et al. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J Clin Microbiol. 2006;44:553–60.PubMed
81.
go back to reference Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954–8.PubMed Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954–8.PubMed
82.
go back to reference Odds FC, van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282–8.PubMed Odds FC, van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282–8.PubMed
83.
go back to reference Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologia. 1994;128:135–7.PubMed Otcenasek M, Buchta V. In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens. Mycopathologia. 1994;128:135–7.PubMed
84.
go back to reference Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251–5.PubMed Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30:251–5.PubMed
85.
go back to reference Van Cutsem J, Van Gerven F, Fransen J, Janssen PA. Treatment of experimental mucormycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy. 1989;35:267–72.PubMed Van Cutsem J, Van Gerven F, Fransen J, Janssen PA. Treatment of experimental mucormycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy. 1989;35:267–72.PubMed
86.
go back to reference Watson DC, Neame PB. In vitro activity of amphotericin B on strains of Mucoraceae pathogenic to man. J Lab Clin Med. 1960;56:251–7.PubMed Watson DC, Neame PB. In vitro activity of amphotericin B on strains of Mucoraceae pathogenic to man. J Lab Clin Med. 1960;56:251–7.PubMed
87.
go back to reference Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated mucormycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.PubMed Spellberg B, Fu Y, Edwards Jr JE, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated mucormycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.PubMed
88.
go back to reference Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556–8.PubMed Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556–8.PubMed
89.
go back to reference Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital- cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMed Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital- cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMed
90.
go back to reference Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51:45–52.PubMed Dannaoui E, Meletiadis J, Mouton JW, et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51:45–52.PubMed
91.
go back to reference Dannaoui E, Afeltra J, Meis J, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708–11.PubMed Dannaoui E, Afeltra J, Meis J, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708–11.PubMed
92.
go back to reference Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses. 2005;48:246–50.PubMed Singh J, Rimek D, Kappe R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses. 2005;48:246–50.PubMed
93.
go back to reference Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581–2.PubMed Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46:1581–2.PubMed
94.
go back to reference Gaviria JM, Grohskopf LA, Barnes R, Root RK. Successful treatment of rhinocerebral mucormycosis: a combined- strategy approach. Clin Infect Dis. 1999;28:160–1.PubMed Gaviria JM, Grohskopf LA, Barnes R, Root RK. Successful treatment of rhinocerebral mucormycosis: a combined- strategy approach. Clin Infect Dis. 1999;28:160–1.PubMed
95.
go back to reference Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17:409–14.PubMed Gaziev D, Baronciani D, Galimberti M, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17:409–14.PubMed
96.
go back to reference Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of mucormycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45:1351–60.PubMed Gleissner B, Schilling A, Anagnostopolous I, et al. Improved outcome of mucormycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45:1351–60.PubMed
97.
go back to reference Hunstad DA, Cohen AH, St Geme 3rd JW. Successful eradication of mucormycosis occurring in a pulmonary allograft. J Heart Lung Transplant. 1999;18:801–4.PubMed Hunstad DA, Cohen AH, St Geme 3rd JW. Successful eradication of mucormycosis occurring in a pulmonary allograft. J Heart Lung Transplant. 1999;18:801–4.PubMed
98.
go back to reference Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary mucormycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:417–20.PubMed Leleu X, Sendid B, Fruit J, et al. Combined anti-fungal therapy and surgical resection as treatment of pulmonary mucormycosis in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;24:417–20.PubMed
99.
go back to reference Linden P, Williams P, Chan KM. Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant. 2000;14:329–39.PubMed Linden P, Williams P, Chan KM. Efficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant. 2000;14:329–39.PubMed
100.
go back to reference Maury S, Leblanc T, Feuihade M, Molina J-M, Schaison G. Successful treatement of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis. 1998;26:200–2.PubMed Maury S, Leblanc T, Feuihade M, Molina J-M, Schaison G. Successful treatement of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis. 1998;26:200–2.PubMed
101.
go back to reference Mazade MA, Margolin JF, Rossmann SN, Edwards MS. Survival from pulmonary infection with Cunninghamella bertholletiae: case report and review of the literature. Pediatr Infect Dis J. 1998;17:835–9.PubMed Mazade MA, Margolin JF, Rossmann SN, Edwards MS. Survival from pulmonary infection with Cunninghamella bertholletiae: case report and review of the literature. Pediatr Infect Dis J. 1998;17:835–9.PubMed
102.
go back to reference Meis JF, Kullberg BJ, Pruszczynski M, Veth RP. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J Clin Microbiol. 1994;32:3078–81.PubMed Meis JF, Kullberg BJ, Pruszczynski M, Veth RP. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J Clin Microbiol. 1994;32:3078–81.PubMed
103.
go back to reference Moses AE, Rahav G, Barenholz Y, et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis. 1998;26:1430–3.PubMed Moses AE, Rahav G, Barenholz Y, et al. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients. Clin Infect Dis. 1998;26:1430–3.PubMed
104.
go back to reference Nenoff P, Kellermann S, Schober R, et al. Rhinocerebral mucormycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Mycoses. 1998;41:365–72.PubMed Nenoff P, Kellermann S, Schober R, et al. Rhinocerebral mucormycosis following bone marrow transplantation in chronic myelogenous leukaemia. Report of a case and review of the literature. Mycoses. 1998;41:365–72.PubMed
105.
go back to reference Okhuysen PC, Rex JH, Kapusta M, Fife C. Successful treatment of extensive posttraumatic soft-tissue and renal infections due to Apophysomyces elegans. Clin Infect Dis. 1994;19:329–31.PubMed Okhuysen PC, Rex JH, Kapusta M, Fife C. Successful treatment of extensive posttraumatic soft-tissue and renal infections due to Apophysomyces elegans. Clin Infect Dis. 1994;19:329–31.PubMed
106.
go back to reference Saltoglu N, Tasova Y, Zorludemir S, Dundar IH. Rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Mycoses. 1998;41:45–9.PubMed Saltoglu N, Tasova Y, Zorludemir S, Dundar IH. Rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Mycoses. 1998;41:45–9.PubMed
107.
go back to reference St-Germain G, Robert A, Ishak M, et al. Infection due to Rhizomucor pusillus: report of four cases in patients with leukemia and review. Clin Infect Dis. 1993;16:640–5.PubMed St-Germain G, Robert A, Ishak M, et al. Infection due to Rhizomucor pusillus: report of four cases in patients with leukemia and review. Clin Infect Dis. 1993;16:640–5.PubMed
108.
go back to reference Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med. 1996;156:337–9.PubMed Strasser MD, Kennedy RJ, Adam RD. Rhinocerebral mucormycosis. Therapy with amphotericin B lipid complex. Arch Intern Med. 1996;156:337–9.PubMed
109.
go back to reference Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–96.PubMed Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–96.PubMed
110.
go back to reference Shoham S, Magill SS, Merz WG, et al. Primary treatment of mucormycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010;48:511–7.PubMed Shoham S, Magill SS, Merz WG, et al. Primary treatment of mucormycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010;48:511–7.PubMed
111.
go back to reference Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–96.PubMed Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–96.PubMed
112.
go back to reference Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents - pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997–2020.PubMed Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents - pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997–2020.PubMed
113.
go back to reference Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310–2.PubMed Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46:2310–2.PubMed
114.
go back to reference Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623–6.PubMed Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623–6.PubMed
115.
go back to reference Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for mucormycosis. Mycoses. 2004;47:159–62.PubMed Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for mucormycosis. Mycoses. 2004;47:159–62.PubMed
116.
go back to reference Mathew R, Kumaravel S, Kuruvilla S, et al. Successful treatment of extensive basidiobolomycosis with oral itraconazole in a child. Int J Dermatol. 2005;44:572–5.PubMed Mathew R, Kumaravel S, Kuruvilla S, et al. Successful treatment of extensive basidiobolomycosis with oral itraconazole in a child. Int J Dermatol. 2005;44:572–5.PubMed
117.
go back to reference Quinio D, Karam A, Leroy JP, et al. Mucormycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol. 2004;42:177–80.PubMed Quinio D, Karam A, Leroy JP, et al. Mucormycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol. 2004;42:177–80.PubMed
118.
go back to reference Dannaoui E, Meis J, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated mucormycosis. Antimicrob Agents Chemother. 2003;47:3647–50.PubMed Dannaoui E, Meis J, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated mucormycosis. Antimicrob Agents Chemother. 2003;47:3647–50.PubMed
119.
go back to reference Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.PubMed Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.PubMed
120.
go back to reference Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for treatment of murine mucormycosis. Antimicrob Agents Chemother. 2009;53:772–5.PubMed Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for treatment of murine mucormycosis. Antimicrob Agents Chemother. 2009;53:772–5.PubMed
121.
go back to reference Van Burik JAH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in mucormycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:E61–5.PubMed Van Burik JAH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in mucormycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:E61–5.PubMed
122.
go back to reference Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for mucormycosis. Antimicrob Agents Chemother. 2006;50:126–33.PubMed Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for mucormycosis. Antimicrob Agents Chemother. 2006;50:126–33.PubMed
123.
go back to reference Brugiere O, Dauriat G, Mal H, et al. Pulmonary mucormycosis (mucormycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation. 2005;80:544–5.PubMed Brugiere O, Dauriat G, Mal H, et al. Pulmonary mucormycosis (mucormycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation. 2005;80:544–5.PubMed
124.
go back to reference Garbino J, Uckay I, Amini K, et al. Absidia posttraumatic infection: successful treatment with posaconazole. J Infect. 2005;51:e135–8.PubMed Garbino J, Uckay I, Amini K, et al. Absidia posttraumatic infection: successful treatment with posaconazole. J Infect. 2005;51:e135–8.PubMed
125.
go back to reference Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (Mucormycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36:1488–91.PubMed Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (Mucormycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36:1488–91.PubMed
126.
go back to reference Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743–51.PubMed Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743–51.PubMed
127.
go back to reference Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.PubMed Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.PubMed
128.
go back to reference Reed C, Ibrahim A, Edwards Jr JE, et al. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968–9.PubMed Reed C, Ibrahim A, Edwards Jr JE, et al. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968–9.PubMed
129.
go back to reference Caldwell J. Effects of high partial pressures of oxygen on fungi. Nature. 1963;197:772–4. Caldwell J. Effects of high partial pressures of oxygen on fungi. Nature. 1963;197:772–4.
130.
go back to reference Karsner HT, Saphir O. Influence of high partial pressures of oxygen on the growth of certain molds. J Infect Dis. 1926;39:231–6. Karsner HT, Saphir O. Influence of high partial pressures of oxygen on the growth of certain molds. J Infect Dis. 1926;39:231–6.
131.
go back to reference Robb SM. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J Gen Microbiol. 1966;45:17–29. Robb SM. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J Gen Microbiol. 1966;45:17–29.
132.
go back to reference Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue mucormycosis complicating diabetes mellitus. Plast Reconstr Surg. 1998;102:822–4.PubMed Bentur Y, Shupak A, Ramon Y, et al. Hyperbaric oxygen therapy for cutaneous/soft-tissue mucormycosis complicating diabetes mellitus. Plast Reconstr Surg. 1998;102:822–4.PubMed
133.
go back to reference Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg. 1988;114:791–4.PubMed Couch L, Theilen F, Mader JT. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg. 1988;114:791–4.PubMed
134.
go back to reference De La Paz MA, Patrinely JR, Marines HM, Appling WD. Adjunctive hyperbaric oxygen in the treatment of bilateral cerebro-rhino-orbital mucormycosis. Am J Ophthalmol. 1992;114:208–11. De La Paz MA, Patrinely JR, Marines HM, Appling WD. Adjunctive hyperbaric oxygen in the treatment of bilateral cerebro-rhino-orbital mucormycosis. Am J Ophthalmol. 1992;114:208–11.
135.
go back to reference Gonzalez CE, Couriel DR, Walsh TJ. Disseminated mucormycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granuloyte colony-stimulating factor. Clin Infect Dis. 1997;24:192–6.PubMed Gonzalez CE, Couriel DR, Walsh TJ. Disseminated mucormycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granuloyte colony-stimulating factor. Clin Infect Dis. 1997;24:192–6.PubMed
136.
go back to reference Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an 11-year experience. Haematologica. 2009;94:1661–8.PubMed Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an 11-year experience. Haematologica. 2009;94:1661–8.PubMed
137.
go back to reference Liles WC, Huang JE, van Burik J-AH, et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175:1012–5.PubMed Liles WC, Huang JE, van Burik J-AH, et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis. 1997;175:1012–5.PubMed
138.
go back to reference Mayer P, Schutze E, Lam C, et al. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis. 1991;163:584–90.PubMed Mayer P, Schutze E, Lam C, et al. Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis. 1991;163:584–90.PubMed
139.
go back to reference Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:11–23. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2004;4:11–23.
140.
go back to reference Pursell K, Verral S, Daraiesh F, et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis. 2003;5:29–37.PubMed Pursell K, Verral S, Daraiesh F, et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: in vitro effect of r-metHuG-CSF (Filgrastim). Transpl Infect Dis. 2003;5:29–37.PubMed
141.
go back to reference Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583–96.PubMed Antachopoulos C, Roilides E. Cytokines and fungal infections. Br J Haematol. 2005;129:583–96.PubMed
142.
go back to reference Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869–76.PubMed Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869–76.PubMed
143.
go back to reference Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin’s lymphoma. Cancer. 1990;66:1904–9.PubMed Yoshida T, Nakamura S, Ohtake S, et al. Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin’s lymphoma. Cancer. 1990;66:1904–9.PubMed
144.
go back to reference Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769–73.PubMed Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23:769–73.PubMed
145.
go back to reference Sahin B, Paydas S, Cosar E, et al. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis. 1996;15:866–9.PubMed Sahin B, Paydas S, Cosar E, et al. Role of granulocyte colony-stimulating factor in the treatment of mucormycosis. Eur J Clin Microbiol Infect Dis. 1996;15:866–9.PubMed
146.
go back to reference Bhatia S, McCullough J, Perry EH, et al. Granulocyte transfusion: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion. 1994;34:226–32.PubMed Bhatia S, McCullough J, Perry EH, et al. Granulocyte transfusion: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion. 1994;34:226–32.PubMed
147.
go back to reference Hester JP, Dignani MC, Anaissie EJ, et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher. 1995;10:188–93.PubMed Hester JP, Dignani MC, Anaissie EJ, et al. Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apher. 1995;10:188–93.PubMed
148.
go back to reference Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997;11:1621–30.PubMed Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997;11:1621–30.PubMed
149.
go back to reference Jendiroba DB, Lichtiger B, Anaissie E, et al. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion. 1998;38:722–8.PubMed Jendiroba DB, Lichtiger B, Anaissie E, et al. Evaluation and comparison of three mobilization methods for the collection of granulocytes. Transfusion. 1998;38:722–8.PubMed
150.
go back to reference Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr Hematol Rep. 2003;2:522–7.PubMed Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr Hematol Rep. 2003;2:522–7.PubMed
151.
go back to reference Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia–new drugs and immunotherapy. Best Pract Res Clin Haematol. 2008;21:683–90.PubMed Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia–new drugs and immunotherapy. Best Pract Res Clin Haematol. 2008;21:683–90.PubMed
152.
go back to reference Langford JD, McCartney DL, Wang RC. Frozen section–guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol. 1997;124:265–7.PubMed Langford JD, McCartney DL, Wang RC. Frozen section–guided surgical debridement for management of rhino-orbital mucormycosis. Am J Ophthalmol. 1997;124:265–7.PubMed
153.
go back to reference Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope. 1984;94:1060–2.PubMed Abedi E, Sismanis A, Choi K, Pastore P. Twenty-five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope. 1984;94:1060–2.PubMed
154.
go back to reference Gupta AK, Mann SB, Khosla VK, et al. Non-randomized comparison of surgical modalities for paranasal sinus mycoses with intracranial extension. Mycoses. 1999;42:225–30.PubMed Gupta AK, Mann SB, Khosla VK, et al. Non-randomized comparison of surgical modalities for paranasal sinus mycoses with intracranial extension. Mycoses. 1999;42:225–30.PubMed
155.
go back to reference Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities. Ophthal Plast Reconstr Surg. 2001;17:62–6.PubMed Pelton RW, Peterson EA, Patel BC, Davis K. Successful treatment of rhino-orbital mucormycosis without exenteration: the use of multiple treatment modalities. Ophthal Plast Reconstr Surg. 2001;17:62–6.PubMed
Metadata
Title
Rhino-Orbital-Cerebral Mucormycosis
Authors
Maria N. Gamaletsou
Nikolaos V. Sipsas
Emmanuel Roilides
Thomas J. Walsh
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 4/2012
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0272-6

Other articles of this Issue 4/2012

Current Infectious Disease Reports 4/2012 Go to the issue

Central Nervous System and Eye Infections (KC Bloch, Section Editor)

CMV Retinopathy in the Antiretroviral Therapy Era: Prevention, Diagnosis, and Management

Central Nervous System and Eye Infections (KC Bloch, Section Editor)

Balamuthia Mandrillaris Amoebic Encephalitis: An Emerging Parasitic Infection

Cardiovascular Infections (DP Levine, Section Editor)

Enterococcal Endocarditis: Can We Win the War?

Cardiovascular Infections (DP Levine, Section Editor)

Q Fever Endocarditis: Does Serology Predict Outcome?

Cardiovascular Infections (DP Devine, Section Editor)

Ventricular Assist Device Infections

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine